Edoxaban: A New Oral Direct Factor Xa Inhibitor

Author： Camm A. John  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.12, 2011-08, pp. : 1503-1526

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivaroxaban, the first oral, direct factor Xa inhibitor

By Fassiadis Nicholas  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 2945-2946

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, an oral direct factor Xa inhibitor

By Piccini Jonathan P   Patel Manesh R   Mahaffey Kenneth W   Fox Keith AA   Califf Robert M  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 925-937

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the oral direct factor Xa inhibitor – betrixaban

By Palladino Michael   Merli Geno   Thomson Lynda  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 11, 2013-11 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty

By Borris Lars C  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 1083-1088

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite